Begelomab

N/A

Report date: 2022/03/07 18:04:56

Base Information

Drug NameBegelomab
Drug Alias Nameanti-CD26 begelomabmurine anti-CD26 BT 5/9BegedinaBegesandSAND-26 +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody murine
Mechanisms of ActionDipeptidyl peptidase IV inhibitors
TargetsDipeptidyl peptidase IV
Therapy Area/IndicationsGraft vs Host DiseaseDermatomyositis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesItalyGermany +[7] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAdienne
China Registration ClassN/A

Develop Information

Active CompaniesAdienne
Inactive CompaniesAdienne Sa
Active IndicationsGraft vs Host DiseaseDermatomyositis
Inactive IndicationsN/A

Other Information

ATC CodeL04AG07
Related LinksN/A